63 results
6-K
EX-99.1
IPHA
Innate Pharma
21 Mar 24
Summary of Consolidated Financial Statements and Notes
9:20am
, 2022
Net income (loss)
Depreciation and amortization
Employee benefits costs
Provisions for charges
Share-based compensation expense
Change
6-K
EX-1.1
rq7m130g34 fxho
6 Feb 24
Current report (foreign)
5:05pm
424B5
ci9q1u9yu83ynfe0cwjj
6 Feb 24
Prospectus supplement for primary offering
5:00pm
F-3
9itoerj 44ibqvh0z
20 Dec 23
Shelf registration (foreign)
4:45pm
F-3
EX-3.1
frm5u1mc
20 Dec 23
Shelf registration (foreign)
4:45pm
6-K
EX-99.2
7uo3ay
14 Sep 23
Innate Pharma Reports First Half 2023 Financial Results and Business Update
6:27am
6-K
EX-99.1
ed5520vcb
14 Sep 23
Innate Pharma Reports First Half 2023 Financial Results and Business Update
6:27am
6-K
EX-99.1
xmhkadtt4 szzzs6fva
14 Sep 23
Innate Pharma S.a. 6-K
6:00am
6-K
EX-1.1
u12k7
26 Apr 23
Current report (foreign)
4:02pm
424B5
no2e7zsz
26 Apr 23
Prospectus supplement for primary offering
4:01pm
20-F/A
EX-4.9
3dal9 qbgwb2q2h
20 Apr 23
Annual report (foreign) (amended)
8:47am
6-K
EX-99.2
o9onud4ib0u rbd
15 Sep 22
Innate Pharma Reports First Half 2022 Financial Results and Business Update
6:12am
6-K
EX-99.1
s9bg9
15 Sep 22
Innate Pharma Reports First Half 2022 Financial Results and Business Update
6:12am
6-K
EX-1.1
g6x1f3h4q s01h
3 May 22
Current report (foreign)
5:08pm